Codagenix
Codagenix is a clinical-stage synthetic biology company specializing in the design and development of live-attenuated vaccines and viral therapeutics for infectious diseases, cancer, and animal health. Utilizing a proprietary platform that combines codon deoptimization and synthetic biology, Codagenix rapidly engineers viral genomes to create stable, broadly immunogenic, and scalable solutions. Its pipeline includes vaccines targeting dengue, RSV, influenza, COVID-19, yellow fever, Zika, and foot-and-mouth disease, as well as virotherapeutics for cancer and animal health. The company partners with academic institutions, global health organizations, and federal agencies to address critical global health challenges.
Industries
N/A
Patents
Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
2024-12-31 • US-12178869-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2024-08-06 • US-12054519-B2
View DetailsLive attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
2023-10-24 • US-11793870-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2022-07-19 • US-11390651-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2020-10-20 • US-10808012-B2
View Details
Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
2024-12-31 • US-12178869-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2024-08-06 • US-12054519-B2
View DetailsLive attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
2023-10-24 • US-11793870-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2022-07-19 • US-11390651-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
2020-10-20 • US-10808012-B2
View DetailsProducts
Live-attenuated tetravalent dengue vaccine targeting all four serotypes using codon-optimized strains for balanced immunity.
Live-attenuated, intranasal vaccine for respiratory syncytial virus designed for adults and pediatric populations.
Intranasal, live-attenuated influenza vaccines capable of rapid adaptation through antigen swapping, targeting broad protection.
Live-attenuated, intranasal vaccine designed using synthetic biology for broad immune stimulation against SARS-CoV-2.
Codon-optimized, live-attenuated vaccine for prevention of Zika virus infection, safe and immunogenic in primate models.
Codon-modified influenza-based virus with anti-tumor immune microenvironment modulation for breast cancer, shown efficacy in animal models.
Live-attenuated tetravalent dengue vaccine targeting all four serotypes using codon-optimized strains for balanced immunity.
Live-attenuated, intranasal vaccine for respiratory syncytial virus designed for adults and pediatric populations.
Intranasal, live-attenuated influenza vaccines capable of rapid adaptation through antigen swapping, targeting broad protection.
Live-attenuated, intranasal vaccine designed using synthetic biology for broad immune stimulation against SARS-CoV-2.
Codon-optimized, live-attenuated vaccine for prevention of Zika virus infection, safe and immunogenic in primate models.
Codon-modified influenza-based virus with anti-tumor immune microenvironment modulation for breast cancer, shown efficacy in animal models.
Expertise Areas
- Live-attenuated vaccine development
- Synthetic biology for viral genome engineering
- Virotherapeutics for oncology
- Preclinical and clinical trial execution
Key Technologies
- Codon deoptimization
- Synthetic biology
- Machine learning-guided sequence analysis
- Cell culture manufacturing
Key People
Executive Chairman & Interim CEO
Co-Founder, President & Chief Scientific Officer
Chief Business Officer
Advisor, Strategy and Regulatory
Advisor, Finance
Executive Chairman & Interim CEO
Co-Founder, President & Chief Scientific Officer
Chief Business Officer
Advisor, Strategy and Regulatory
Advisor, Finance
News & Updates
Named one of five finalists for the Buzz of BIO contest, recognizing innovation in private therapeutic biotech.
Describes preclinical protection of a live-attenuated COVID-19 vaccine candidate in animal model.
Explores tumor immune modulation by codon-modified influenza virus-based virotherapeutic.
Preclinical safety and immunogenicity outcomes of a live-attenuated SARS-CoV-2 vaccine candidate.
Award for development of stabilized oral polio vaccine candidates to address public health needs.
Received $5.88 million award from US Department of Defense for advancing dengue vaccine into the clinic (complements previous $4.4M award in 2022).
Named one of five finalists for the Buzz of BIO contest, recognizing innovation in private therapeutic biotech.
Describes preclinical protection of a live-attenuated COVID-19 vaccine candidate in animal model.
Explores tumor immune modulation by codon-modified influenza virus-based virotherapeutic.
Preclinical safety and immunogenicity outcomes of a live-attenuated SARS-CoV-2 vaccine candidate.
Award for development of stabilized oral polio vaccine candidates to address public health needs.
Received $5.88 million award from US Department of Defense for advancing dengue vaccine into the clinic (complements previous $4.4M award in 2022).